% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zhao:291282,
      author       = {X. Zhao$^*$ and Y. Zhang$^*$ and O. Trejo-Cerro and E.
                      Kaplan$^*$ and Z. Li$^*$ and F. Albertsboer$^*$ and N. El
                      Hammiri$^*$ and F. C. Mariz$^*$ and L. Banks and S.
                      Ottonello and M. Müller$^*$},
      title        = {{A} safe and potentiated multi-type {HPV} {L}2-{E}7
                      nanoparticle vaccine with combined prophylactic and
                      therapeutic activity.},
      journal      = {npj vaccines},
      volume       = {9},
      number       = {1},
      issn         = {2059-0105},
      address      = {[London]},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2024-01365},
      pages        = {119},
      year         = {2024},
      note         = {#EA:D335#LA:D335#},
      abstract     = {Persistent infection with high-risk human papillomavirus
                      (HPV) is widely recognized as the primary cause of cervical
                      and other malignant cancers. There are six licensed
                      prophylactic vaccines available against HPV, but none of
                      them shows any significant therapeutic effect on
                      pre-existing infections or lesions. Thus, a prophylactic
                      vaccine also endowed with therapeutic activity would afford
                      protection regardless of the vaccine recipients
                      HPV-infection status. Here, we describe the refinement and
                      further potentiation of a dual-purpose HPV nanoparticle
                      vaccine (hereafter referred to as cPANHPVAX) relying on
                      eight different HPV L2 peptide epitopes and on the E7
                      oncoantigens from HPV16 and 18. cPANHPVAX not only induces
                      anti-HPV16 E7 cytotoxic T-cell responses in C57BL/6 mice,
                      but also anti-HPV18 E7 T-cell responses in transgenic mice
                      with the A2.DR1 haplotype. These cytotoxic responses add up
                      to a potent, broad-coverage humoral (HPV-neutralizing)
                      response. cPANHPVAX safety was further improved by deletion
                      of the pRb-binding domains of E7. Our dual-purpose vaccine
                      holds great potential for clinical translation as an
                      immune-treatment capable of targeting active infections as
                      well as established HPV-related malignancies, thus
                      benefiting both uninfected and infected individuals.},
      cin          = {D335 / D130},
      ddc          = {610},
      cid          = {I:(DE-He78)D335-20160331 / I:(DE-He78)D130-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38926425},
      doi          = {10.1038/s41541-024-00914-z},
      url          = {https://inrepo02.dkfz.de/record/291282},
}